Abstract Background: Hepatocelluar carcinoma (HCC) is a major health problem in Egypt as well as in many countries. Transarterial chemoemoblization (TACE) is a treatment modality applicable to locally advanced HCC beyond surgery or ablative therapies and is associated with survival improvements. The aim of this study was to assess the outcomes of TACE in our center over the past four years. Methods: This is a retrospective cohort study that included 221 patients with locally advanced HCC treated with TACE in a single center between the years 2007 and 2010. The median age was 57 years with male predominance. Liver cirrhosis, viral hepatitis and Bilharziasis were encountered in 64%, 31% and 8% of patients, respectively. Abdominal pain was the most common presenting symptom (67%). Most cases were diagnosed based on radiology (57%) with a TNM stage I or II (73%) and a median AFP value of 150 ng/mL. Results: 221 patients received 440 cycles of TACE with a median of 2 cycles per patient. Cisplatin and doxorubicin (50 mg per cycle, each) were the most commonly used drugs. Impaired liver function was the most common toxicity. Liver cell failure occurred in 17% of patients. An objective tumor response was achieved in 44% of cases. The median overall survival (OS) was 16 months (95% CI, 13-19 months) and the median progression free survival (PFS) was 6 months (95% CI,
4.3-7.8 months). Responding patients, Child-Pugh class A and patients receiving standard doses of chemotherapy had a significantly better OS than their counterparts. Only Child-Pugh class A was associated with significantly longer PFS (p < 0.001). Conclusion: TACE produces reasonable responses and fair survival rates in locally advanced HCC but with noticeable toxicities. Proper patients' selection and prompt liver support are mandates for improving TACE outcomes.
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Background
Hepatocellular carcinoma (HCC) is the most common form of primary liver cancer. Globally, liver cancer is the 5th and 7th most common cancer in men and women, respectively. Most of HCC burden lies in developing countries. The regions of high incidence include Eastern and South-Eastern Asia, Middle and Western Africa. Worldwide, it is the third most common cause of cancer deaths [1] . In many Egyptian regional registries, liver cancer is the first cancer in men and the second in women [2] . In Gharbiah population-based cancer registry, liver cancer represents 12.7% of male cancers and 3.4% of female cancers [3] .
Risk factors for HCC are many and include viral hepatitis B and C (HBV and HCV, respectively), cirrhosis, aflatoxins, alcohol, smoking and male gender [4] . These risk factors vary among countries, but chronic infections with HBV and HCV are the most important precursors for HCC development on a global scale. Together, HBV and HCV account for over 80% of liver cancer cases worldwide [5] . In Egypt, HCV is the main risk factor for HCC where 71% of HCC cases are positive for anti-HCV antibodies [6] . The Egyptian Ministry of Health estimated that the incidence of HCV infection among Egyptians is 6.9/100,000 persons per year [7] . The 2008 Egypt Demographic and Health survey (EDHS) showed that almost 15% of the $11,000 tested populations had HCV antibodies in their blood indicating exposure and 10% were positive for HCV RNA test indicating active infection. Prevalence was higher among rural than urban areas, among men than women and among older than younger populations [8] .
Surgical resection or liver transplantation provides the best results in appropriate candidates. When surgery is precluded, local non-surgical therapies like intra-lesional ethanol injection or radiofrequency thermal ablation can be used for smaller tumors. Transarterial chemoembolization (TACE) provides modest survival advantage in patients with preserved liver function (Child-Pugh class A) and larger or multinodular tumors. TACE can be used as holding or bridging therapy prior to liver resection or transplantation. TACE may also be used as a sole therapy for advanced liver tumors not eligible for surgery [9] . Of the different systemic therapies, only the oral multikinase inhibitor Sorafenib showed a clear survival benefit in advanced HCC [10] . Sorafenib plus doxorubicin compared with doxorubicin monotherapy resulted in significantly greater median time to progression, overall survival, and progressionfree survival [11] .
It is not clearly known whether TACE in Egyptian HCC patients produces equivalent outcomes to those reported in international studies. The aim of this study was to evaluate TACE as a method of therapy in advanced HCC in Egyptian patients regarding prevailing indications, drugs used, safety and efficacy of the procedure.
Patients and methods
This is a retrospective cohort study that included patients diagnosed with advanced HCC and treated with TACE at the National Cancer Institute (NCI), Cairo University, between January 2007 and December 2010. The study was approved by the NCI Institutional Review Board. The medical records of eligible patients were retrieved and relevant information extracted.
The primary endpoint was overall survival (OS). Secondary endpoints were progression free survival (PFS), response rates (RR) and toxicity of the TACE procedure. OS was defined as the time in months from the date of diagnosis until death or last follow up. PFS was defined as the time from first TACE until tumor progression, clinical deterioration, death or last follow up. Tumors were staged according to the AJCC Cancer Staging Manual, 6th edition [12] . Response was assessed following each cycle and prior to the next cycle. Responses were assessed using the RECIST V1.0 criteria [13] while TACE toxicities were graded according to CTCAE v3.0 [14] .
Statistical analyses were performed using SPSSÒ software version 15, Chicago, IL. Numerical variables were presented as means and standard deviations (SD) or medians and ranges and groups were compared using the student t-test or MannWhitney U test. Survival was estimated using the Kaplan-Meier method and groups were compared using the log-rank test. A p value 60.05 was considered significant.
Baseline clinico-pathological characteristics
The study included 221 locally advanced HCC patients whose ages ranged between 38 and 84 years with a mean of 57 years (Table 1) . Most cases (57%) were diagnosed based on classic enhancement on radiology [15, 16] and histological confirmation was available for 43% of cases. Elevated AFP (>200 ng/dL) supplemented the diagnosis in 29% of cases. Male to female ratio was 6.4:1. Cirrhosis and viral hepatitis were documented in 64% and 32% of patients, respectively. HBV infection was encountered in 1/71 patients (1.4%) and the remaining 70 patients (98.6%) had HCV infection. A past history suggestive of Bilharziasis was encountered in 8 patients (4%), only. Of 221 patients, 40 (18%) had concomitant general disease; mainly DM (n = 18) followed by hypertension (n = 9). Among 130 patients with documented presenting symptoms, pain was encountered in 87 patients (67%). Most patients had an ECOG performance status (PS) of 2 and a Child-Pugh class B. The median Child-Pugh score was 7 (range, 5-9). In 81/94 patients with histological proof, the most common histological grade was grade II (69%). Single tumors were encountered in 51% of cases. The median maximum dimension of the dominant lesion was 6 cm (range, 1.2-19 cm). T1 was encountered in 55% of cases. The commonest TNM stage was I (50%) followed by II, III and IV. Lymph node, vascular invasion and distant metastasis were found in a minority (5%, 3% and 2%, respectively) and the liver was the burdensome site in all of these cases. The commonest Okuda stage was II (76%). The median Okuda score was 1 (range, 0-3). The Median Cancer of the Liver Italian Program (CLIP) score was 2 (range, 0-4). The median baseline value for AFP was 150 (range, 1-283,903) ng/mL, for INR 1.1 (range, 1.0-1.9), for Hemoglobin 13 (range, 7.4-18.7) g/dL, for WBC's 5.7 (range, 2.6-18.7) 1000 cell/mL, and for platelets 150 (range, 40-740) 1000 cell/mL.
Results

TACE treatments
The 221 patients included in the study received 440 cycles of TACE ( Table 2 ). The median number of TACE sessions per patient was 2 (range, 1-8). Almost half of the patients (50%) received one cycle only and 3 quarters did not receive more than 2 cycles. Cisplatin, doxorubicin, and epirubicin were used in 220, 213 and 8 patients (99.5%, 96% and 4%, respectively). Except one patient who received doxorubicin only, all received cisplatin in combination with either doxorubicin or epirubicin. A fixed dose of 50 mg cisplatin and 50 mg doxorubicin or epirubicin was used in 214/221 patients (97%) and a higher dose (100 mg) of cisplatin and/or doxorubicin/epirubicin was used in 7 patients (3%). The embolic material used was Lipiodol in all cases while gelfoam was used in addition to lipiodol in about one third of cases especially those with large tumor size. Super selection using microcatheter techniques were used in 60% of cases but not in old cases.
TACE toxicities
Out of 221 patients, 89 (40%) were documented to have evidence of toxicities either clinical, laboratory or both (Table 2) . Clinical toxicities (fever, abdominal pain, nausea) were encountered in 47% of patients (27% as the sole toxicity and 20% combined with lab toxicities). Manifestations of liver cell impairment (ascites, jaundice, bleeding) occurred in 36/42 patients (87%). It progressed to overt liver cell failure in 15 patients (17%). Venous thrombosis occurred in 3/42 patients (2 patients with portal vein thrombosis and one case with hepatic vein thrombosis). Diarrhea and febrile neutropenia were encountered in one patient each. Laboratory toxicities were encountered in 73% of patients (53% as the sole toxicity and 20% combined with clinical toxicities). The main laboratory toxicities were elevated liver enzymes in 46/65 patients (71%), elevated bilirubin in 11/65 patients (17%), thrombocytopenia in 4/65 patients (6%), decreased serum albumin and elevated serum creatinine in 2 patients (3%), each. Most of the clinical and laboratory toxicities were grade 3 or 4 that mandated cessation of TACE treatments in 30 patients (33.7%). Mortality attributable to TACE complications was encountered in 19 patients due to liver cell failure in 17 patients, febrile neutropenia in one patient and acute renal failure in one patient. Toxicities were encountered more in the patients who received higher doses of drugs and with higher baseline Child-Pugh score.
Tumor response to TACE
Response assessment was documented in 151/211 patients (68%), the remaining 70 patients were lost to follow up before response assessment. Tumor response was achieved in 43.7% of the assessed cases that was complete in 19.2% and partial in 24.5% of patients. The disease was stable in 10.6% of patients and 45.7% of patients suffered progressive disease that was commonly local in the liver and less commonly regional (LN) or distant (74%, 7% and 19%).
Overall survival
As documented in the last visit and after a median follow up period of 18 months (range, 1-66 months), 104/221 patients (47%) were alive and 117/221 (53%) were dead. The median OS was 16 months (95% CI, 13-19) (Figure 1 ). The 1-, 2-and 3-year OS rates ± standard errors were 57.8% ± 3.7%, 33.6% ± 4.3% and 22.0% ± 4.4%, respectively. The impact of various prognostic factors on OS is shown in Table 3 .
Responding patients (CR or PR), Child-Pugh class A, and patients who received standard doses of chemotherapy had a significantly better OS (p < 0.05 for all). AFP < 200 ng/mL was associated with better OS but was not statistically significant. Age, gender, PS, TNM staging, number of lesion and number of sessions had no impact on OS.
Progression free survival
The median progression free survival was 6 months (95% CI, 4.3-7.8) (Figure 2 ). The 1-and 2-year PFS rates ± standard error were 35.8% ± 3.9% and 13.1% ± 3.6%, respectively. Child-Pugh A was associated with significantly longer PFS (Table 3) . Male gender, AFP < 200 ng/mL, and patients who received only one TACE session were associated with longer but not statistically significant PFS.
Discussion
The liver has a unique dual blood supply from both the portal vein and the hepatic artery. The normal parenchyma of the liver receives two thirds of its necessary blood supply from the portal vein and the remaining from the hepatic artery. However, it is well known that vascularization of HCC is mostly dependent on the hepatic artery [17] . This characteristic of HCC not only justifies the diagnostic use of contrast enhanced CT and MRI, but also provides a basic rationale for transarterial therapy as an effective treatment of HCC [18] . The goals of TACE are to deliver concentrated chemotherapy directly to the tumors and to reduce the blood supply to the tumor, causing ischemic necrosis [19] . The mean age of 57 years and the male predominance in the current study mimics HCC population in Egypt, at large [20] [21] [22] as well as some other countries [23] . The male predominance may be explained by differences in exposure to risk factors. However, sex hormones have been linked with HCC development [24, 25] . In many countries like Japan, southern Europe and the USA, Saudi Arabia and Egypt, HCV is the main risk factor for HCC. With the implementation of vaccination programs against HBV, the importance and the prevalence of HCV as an etiological factor for HCC is increasing [1] . In Italy, for example, the incidence of HCV as a risk factor was 50.4% while HBV was 7.7% [26] . Similarly, incidence of HBV and HCV was 71% and 15% in HCC patients in India, respectively [27] . On the other hand, HBV is endemic in China and studies on HCC in Chinese population showed that the incidence of HBV was 81% and that of HCV was 4% [23] . In the current study, viral hepatitis was documented in one third of patients (71/221) and HCV was predominant (32% of patients) whereas HBV was encountered only in one patient. HCV predominance was similar to prior reports from Egypt [28] [29] [30] [31] [32] [33] [34] .
Despite HCC can develop in absence of cirrhosis, 60-80% of persons with HCC have underlying cirrhosis, possibly approaching 90% in countries like the USA [35] . In the current study, cirrhosis was documented in 64% of cases and this is lower than reports from countries like Germany [36] and in the USA [37] where cirrhosis was encountered in more than 90% of HCC patients. We believe this represents underreporting of cirrhosis rather than a true incidence given the retrospective nature of the current study.
The mean tumor size in the current study was 6.4 cm which was similar to the 7 cm size reported by Herber et al. and Lewandowski et al. [36, 37] and smaller than the 10.5 cm reported by Shi et al. [39] . It was larger than the 4.9 CM reported by Llovet et al. [40] . While this reflects variation among trials, it also emphasized that these patients have advanced disease beyond surgery or local/ablative therapy.
The objective response rates of TACE have been reported between 15% and 61% [17, 38, [40] [41] [42] [43] [44] [45] [46] [47] [48] [49] [50] [51] and complete responses may reach up to 20-35% [52] . In the current study, the response rate was 43.7% with CR in 19.2% and PR in 24.5%. While these figures go with those mentioned in the literature, it should be noted that responses were assessable in only 151/221 patients as the remaining 50 patients did not show up following the 1st TACE mostly due to clinical deterioration because of TACE toxicities or tumor progression. If these were considered as non responders, the response rates would be lower (66/221, 30%). The fair responses to TACE call for their integration in the treatment plan for HCC e.g. as a neoadjuvant measure to be followed by surgery or local ablative therapies.
TACE is very stressful for HCC patients and can have plenty of complications particularly with underlying causative factors (e.g. compromised liver function, main portal vein thrombosis, biliary tract obstruction, a previous history of bile duct surgery) or inadvertent techniques (e.g. Lipiodol or chemotherapeutic overdosage, nonselective TACE or hepatic artery occlusion with repeated treatments) [17] . The most common complication is post embolization syndrome (PES) that occurs in 60-80% of cases and the most serious is hepatic failure that occurs in a median of 8% of cases [52] . In the current study, toxicities of TACE were assessable only in 89 patients (40% of the total). The reasons for this low reporting include defective documentation particularly with the retrospective nature of the study, the noticeable no-show after the 1st TACE (50/221, 21%) and the split follow up of TACE patients at NCI between Medical Oncologists and Interventional radiologist with the latter being involved in the diagnosis and management but with limited access to documentation in the paper medical records. PES was encountered in all patients and hepatic failure was documented in 15/89 patients (17%). The relatively low documentation of toxicities might have contributed to the high rates of PES and liver failure.
Almost half of the patients received one cycle only of TACE and 3 quarters did not receive more than two cycles. This may reflect the poor tolerance to the procedure as most of the patients presented with performance status of 2 and half of them were of the Child-Pugh class B. This highlights the urgent need for proper patient selection to minimize TACE complications and improve its tolerance [17, 39] .
Some randomized controlled trials [38, 47] and meta-analysis [40, 53] have demonstrated the effectiveness of TACE on overall survival with improvement of the two-year survival rates and increase in the median OS survival compared to palliative care. In the current study, the 1-, 2-and 3-year OS rates of 58%, 34% and 22%, respectively are similar to the 57%, 31% and 26% respective rates reported by Lo et al. [38] and fit within 19%-63% 2-year OS rates reported in the meta analysis by Llovet et al. [40] . However, they were lower than the 82%, 63% and 29% OS rates reported by Llovet [47] . The better figures with Llovet et al. report could be the inclusion of patients with favorable prognosis than the current study where the liver tumors are smaller (4.9 cm vs. 6.3 cm), more ChildPugh A class patients (79% vs. 47%) and more patients with PS 0-1 (97.5% vs. 19%). In the current study the median OS was 16 months, similar to what is reported by several authors [30] [31] [32] [33] 38] . However, it was lower than the median of $30 months that is reported by Llovet et al. and Cabibbo et al. [47, 54] and higher than the median of 10.4 months reported by Shi et al. [39] . The main reason for this variation is the differences in patients' populations and their disease extent and the degree of cirrhosis with patients in the current study having baseline characteristics that confer moderate prognosis between trials with better and worse survival rates, as mentioned above.
Similar to Lo et al., Shi et al. and Llovert et al. [38, 39, 47] , OS was significantly longer in patients with Child-Pugh class A compared to B. This highlights the importance of patient selection for TACE. Also in agreement with Lo et al. and Ebied Figure 1 Overall survival of 221 patients with locally advanced hepatoma receiving Transarterial chemoembolization (continuous line is the main survival curve, dotted curves represent the upper and lower boundary of the 95% confidence interval). et al. [38, 55] , OS was significantly longer in responding patients compared to non-responding patients.
The median PFS in this study was 9 months which is relatively similar to a previous TACE report from Egypt where the median PFS was 32 weeks [56] . Child-Pugh class A was associated with significantly longer PFS than class B.
To the best of our knowledge, the current study is one of the largest series that reports on TACE. It also reports a common and mostly unified practice in the largest Egyptian cancer center where HCC is prevailing. On the other hand, the retrospective nature of the present study has its limitations [57] . However, we have done our maximal efforts to have a well conducted study that reflects the community practice e.g. survival data were updated using telephone calls to the patients.
Conclusion
TACE produces reasonable responses and fair survival rates in locally advanced HCC but with noticeable toxicities. Better case selection that included patients with adequate liver function (Child-Pugh A) and good performance status as well as prompt liver support are mandates for improving TACE outcomes. Tailoring drug doses to individual patients is advisable. Less toxic new TACE strategies that may increase efficacy or decrease toxicity should be explored on a wide scale at the Egyptian NCI. These include drug-eluting beads and radioactive pharmaceuticals. It is preferable to have TACE patients admitted for few days following the procedure to observe and manage complications. The management of HCC patients should be through a harmonized multidisciplinary service. Measures to improve documentation of patients' medical information in the medical records are urgently advisable.
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